

George D Dangas, Mscai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1198331/publications.pdf>

Version: 2024-02-01

313
papers

20,844
citations

22099

59
h-index

11030

137
g-index

557
all docs

557
docs citations

557
times ranked

18293
citing authors

#	ARTICLE	IF	CITATIONS
1	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	1.0	2,687
2	Bivalirudin during Primary PCI in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2008, 358, 2218-2230.	13.9	1,693
3	Angiographic Patterns of In-Stent Restenosis. <i>Circulation</i> , 1999, 100, 1872-1878.	1.6	1,151
4	A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1393-1399.	1.2	1,127
5	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042.	13.9	683
6	In-Stent Restenosis in the Drug-Eluting Stent Era. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1897-1907.	1.2	663
7	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2224-2234.	1.2	445
8	Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1945-1954.	1.2	383
9	Contrast-Associated Acute Kidney Injury. <i>New England Journal of Medicine</i> , 2019, 380, 2146-2155.	13.9	363
10	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020, 382, 120-129.	13.9	362
11	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019. <i>JAMA Network Open</i> , 2020, 3, e2013136.	2.8	344
12	Prosthetic Heart Valve Thrombosis. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2670-2689.	1.2	332
13	Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1298-1310.	1.2	314
14	Characterization of Myocardial Injury in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2043-2055.	1.2	303
15	Stroke After Coronary Artery Bypass. <i>Stroke</i> , 2001, 32, 1508-1513.	1.0	299
16	Impact of the Everolimus-Eluting Stent on Stent Thrombosis. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1569-1577.	1.2	258
17	Atherosclerotic Plaque Burden and CK-MB Enzyme Elevation After Coronary Interventions. <i>Circulation</i> , 2000, 101, 604-610.	1.6	256
18	Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. <i>Circulation</i> , 2011, 123, 1745-1756.	1.6	222

#	ARTICLE	IF	CITATIONS
19	Creatine Kinase-MB Enzyme Elevation Following Successful Saphenous Vein Graft Intervention Is Associated With Late Mortality. <i>Circulation</i> , 1999, 100, 2400-2405.	1.6	217
20	Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. <i>European Heart Journal</i> , 2014, 35, 1533-1540.	1.0	210
21	Differential Impact on Survival of Electrocardiographic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention. <i>Circulation</i> , 2001, 104, 642-647.	1.6	207
22	Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020, 382, 130-139.	13.9	194
23	Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 629-638.	1.2	190
24	Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 914-922.	1.1	181
25	Treatment of Higher-Risk Patients With an Indication for Revascularization. <i>Circulation</i> , 2016, 134, 422-431.	1.6	181
26	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	6.1	180
27	Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2733-2744.	1.2	160
28	Stent Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1081-1092.	1.1	159
29	Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002475.	1.4	148
30	P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2021, 373, n1332.	3.0	144
31	Alignment of Transcatheter Aortic-Valve Neo-Commissures (ALIGN TAVR). <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1030-1042.	1.1	143
32	Treatment of In-Stent Restenosis With Excimer Laser Coronary Angioplasty Versus Rotational Atherectomy. <i>Circulation</i> , 2000, 101, 2484-2489.	1.6	140
33	Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2711-2722.	1.2	139
34	Long-Term Outcome of PCI Versus CABG in Insulin and Non-Insulin-Treated Diabetic Patients. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1189-1197.	1.2	134
35	Meta-analysis on the impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcome. <i>International Journal of Cardiology</i> , 2015, 187, 90-96.	0.8	126
36	Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course. <i>Journal of the American College of Cardiology</i> , 1999, 34, 663-671.	1.2	123

#	ARTICLE	IF	CITATIONS
37	Ticagrelor With or Without Aspirin After ComplexÂPCI. Journal of the American College of Cardiology, 2020, 75, 2414-2424.	1.2	122
38	Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents. Journal of the American College of Cardiology, 2017, 69, 3055-3066.	1.2	117
39	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2015, 66, 2860-2868.	1.2	116
40	Sexâ€based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONSâ€AMI trial. Catheterization and Cardiovascular Interventions, 2015, 85, 359-368.	0.7	112
41	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. American Heart Journal, 2016, 182, 125-134.	1.2	108
42	Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2012, 5, 1097-1105.	1.1	101
43	Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER-collaboration. European Heart Journal, 2019, 40, 456-465.	1.0	100
44	Contrastâ€induced nephropathy. Catheterization and Cardiovascular Interventions, 2008, 71, 62-72.	0.7	99
45	Bifurcation stenting with drug-eluting stents: a systematic review and meta-analysis of randomised trials. EuroIntervention, 2009, 5, 475-484.	1.4	98
46	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. JAMA Cardiology, 2019, 4, 1092.	3.0	97
47	Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. American Heart Journal, 2017, 184, 81-87.	1.2	95
48	Open Versus Endovascular Stent Graft Repair of Abdominal Aortic Aneurysms. JACC: Cardiovascular Interventions, 2012, 5, 1071-1080.	1.1	94
49	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal, 2022, 43, e17-e25.	1.0	92
50	Cerebral Embolic Protection During TAVR. Journal of the American College of Cardiology, 2017, 69, 465-466.	1.2	88
51	Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus. Journal of the American College of Cardiology, 2014, 63, 2111-2118.	1.2	85
52	Spontaneous coronary artery dissection. International Journal of Cardiology, 2014, 175, 8-20.	0.8	82
53	Sex Differences in Transfemoral Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2019, 74, 2758-2767.	1.2	71
54	Predictors, Incidence, and Outcomes of Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation Complicated by Stroke. Circulation: Cardiovascular Interventions, 2019, 12, e007546.	1.4	71

#	ARTICLE	IF	CITATIONS
55	Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: Findings from a large multiethnic registry. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 859-866.	0.7	69
56	A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. <i>Lancet, The</i> , 2021, 398, 1974-1983.	6.3	69
57	Incidence, Predictors, and Implications of Reinfarction After Primary Percutaneous Coronary Intervention in ST-Segmentâ€“Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 543-551.	1.4	67
58	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. <i>Journal of the American College of Cardiology</i> , 2020, 75, 578-586.	1.2	66
59	Viral Coagulopathy in Patients With COVID-19: Treatment and Care. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962093677.	0.7	64
60	Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillationâ€“Rationale and design of the ENVISAGE-TAVI AF trial. <i>American Heart Journal</i> , 2018, 205, 63-69.	1.2	62
61	Meta-Analysis of Trials on Mortality After Percutaneous Coronary Intervention Compared With Medical Therapy in Patients With Stable Coronary Heart Disease and Objective Evidence of Myocardial Ischemia. <i>American Journal of Cardiology</i> , 2015, 115, 1194-1199.	0.7	60
62	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2403-2413.	1.2	60
63	Thrombo-embolic prevention after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2017, 38, 3341-3350.	1.0	59
64	Neurological Outcomes With Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2124-2133.	1.1	58
65	Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1846-1857.	1.2	58
66	Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease. <i>European Heart Journal</i> , 2016, 37, 3440-3447.	1.0	57
67	Complete Revascularization During Primary Percutaneous Coronary Intervention Reduces Death and Myocardial Infarction in Patients With Multivessel Disease. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 833-843.	1.1	55
68	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007411.	1.4	55
69	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1349-1357.	1.1	54
70	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , 2021, 42, 4624-4634.	1.0	54
71	Effect of Anemia on Frequency of Short- and Long-Term Clinical Events in Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). <i>American Journal of Cardiology</i> , 2014, 114, 1823-1829.	0.7	53
72	Left Ventricular Thrombus Following Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1010-1022.	1.2	53

#	ARTICLE	IF	CITATIONS
73	The current role and future prospects of D-dimer biomarker. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 175-184.	1.4	52
74	Clinical Outcomes Following Stent Thrombosis Occurring In-Hospital Versus Out-of-Hospital. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1752-1759.	1.2	51
75	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 674-684.	1.1	51
76	Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2309-2316.	1.2	49
77	Feasibility of Repeat TAVR After SAPIEN 3 TAVR. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1290-1292.	1.1	49
78	Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 255-255.	1.4	48
79	Clinical Outcome of Nonculprit Plaque Ruptures in Patients With Acute Coronary Syndrome in the PROSPECT Study. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 397-405.	2.3	47
80	Inverse relationship between body mass index and coronary artery calcification in patients with clinically significant coronary lesions. <i>Atherosclerosis</i> , 2012, 221, 176-182.	0.4	46
81	Cerebral Embolism During Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2016, 68, 589-599.	1.2	45
82	Impact of Initial Evolut Transcatheter Aortic Valve Replacement Deployment Orientation on Final Valve Orientation and Coronary Reaccess. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008044.	1.4	43
83	Radial versus femoral access for coronary interventions: An updated systematic review and meta-analysis of randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1387-1396.	0.7	42
84	Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2017-2025.	1.1	41
85	Relation of Baseline Hemoglobin Levels and Adverse Events in Patients With Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy and Harmonizing) <i>Tj ETQq1 1 0.784314 rgBT /Ov</i> <i>Journal of Cardiology</i> . 2017, 119, 1710-1716.	0.7	39
86	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1461-1469.	1.1	37
87	Colchicine in Cardiovascular Disease: In-Depth Review. <i>Circulation</i> , 2022, 145, 61-78.	1.6	37
88	Prognostic Utility of the SYNTAX Score in Patients With Single Versus Multivessel Disease Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage) <i>Tj ETQq0 0 0.07 BT /Over</i> <i>Journal of Cardiology</i> . 2017, 119, 1710-1716.	0.7	36
89	Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1374-1381.	0.7	35
90	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , 2021, 144, 1323-1343.	1.6	35

#	ARTICLE	IF	CITATIONS
91	Prognostic Value of Access Site and Nonaccess Site Bleeding After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 622-630.	1.1	34
92	Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization. <i>Nature Reviews Cardiology</i> , 2022, 19, 195-208.	6.1	34
93	Contemporary overview and clinical perspectives of chronic total occlusions. <i>Nature Reviews Cardiology</i> , 2014, 11, 458-469.	6.1	33
94	The relationship among extent of lipid-rich plaque, lesion characteristics, and plaque progression/regression in patients with coronary artery disease: a serial near-infrared spectroscopy and intravascular ultrasound study. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 81-87.	0.5	32
95	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 59 Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2015, 116, 845-852.	0.7	32
96	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1890-1901.	1.1	32
97	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	32
98	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 28-38.	1.1	31
99	Effect of a Contrast Modulation System on Contrast Media Use and the Rate of Acute Kidney Injury After Coronary Angiography. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1601-1610.	1.1	31
100	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1688-1703.	1.1	31
101	Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 753-766.	1.1	31
102	Percutaneous recanalization of chronic total occlusions: Wherein lies the body of proof?. <i>American Heart Journal</i> , 2013, 165, 133-142.	1.2	30
103	Meta-Analysis of Randomized Trials Comparing the Effectiveness of Different Strategies for the Treatment of Drug-Eluting Stent Restenosis. <i>American Journal of Cardiology</i> , 2014, 114, 1339-1346.	0.7	30
104	Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	30
105	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 829-844.	6.1	30
106	Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). <i>American Journal of Cardiology</i> , 2015, 116, 37-42.	0.7	28
107	Types of myocardial injury and mid-term outcomes in patients with COVID-19. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 438-446.	1.8	28
108	Transfemoral TAVR in Nonagenarians. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 911-920.	1.1	27

#	ARTICLE	IF	CITATIONS
109	Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. <i>American Heart Journal</i> , 2020, 219, 1-8.	1.2	27
110	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 444-456.	1.1	27
111	Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2021, 6, 1032.	3.0	27
112	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 855.	3.0	25
113	Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial. <i>EuroIntervention</i> , 2013, 8, 1033-1039.	1.4	25
114	Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 483-493.	1.0	24
115	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006144.	1.4	24
116	Third-Generation Balloon and Self-Expandable Valves for Aortic Stenosis in Large and Extra-Large Aortic Annuli From the TAVR-LARGE Registry. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009047.	1.4	24
117	Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute ST-segment elevation myocardial infarction: Results of the HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 335-342.	0.7	22
118	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 53-65.	1.1	22
119	Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. <i>Canadian Journal of Cardiology</i> , 2018, 34, 319-329.	0.8	22
120	Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 492-502.	1.4	22
121	Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. <i>EuroIntervention</i> , 2014, 10, 312-319.	1.4	22
122	Culprit-lesion only versus complete multivessel percutaneous intervention in ST-elevation myocardial infarction: A systematic review and meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2016, 220, 251-259.	0.8	21
123	Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome after drug-eluting stent implantations. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 573-581.	0.7	21
124	1-Year Clinical Outcomes of All-Coroner Patients Treated With the Dual-Therapy COMBO Stent. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1969-1978.	1.1	21
125	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008226.	1.4	21
126	Sex-Related Outcomes of Medical, Percutaneous, and Surgical Interventions for Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1407-1425.	1.2	21

#	ARTICLE	IF	CITATIONS
127	Influence of final kissing balloon inflation on long-term outcomes after PCI of distal left main bifurcation lesions in the EXCEL trial. <i>EuroIntervention</i> , 2020, 16, 218-224.	1.4	20
128	SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 557-567.	1.4	20
129	Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1997-2005.	1.8	19
130	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1638-1646.	0.7	19
131	Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial). <i>American Journal of Cardiology</i> , 2019, 123, 1494-1500.	0.7	19
132	Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. <i>American Journal of Cardiology</i> , 2016, 117, 1703-1713.	0.7	18
133	Comparison of Local Versus General Anesthesia Following Transfemoral Transcatheter Self-Expanding Aortic Valve Implantation (from the Transcatheter Valve Therapeutics Registry). <i>American Journal of Cardiology</i> , 2019, 123, 419-425.	0.7	18
134	Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 645-654.	1.1	17
135	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007133.	1.4	17
136	Early Adverse Impact of Transfusion After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009026.	1.4	17
137	Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). <i>American Journal of Cardiology</i> , 2016, 117, 192-200.	0.7	16
138	The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E112-E119.	0.7	16
139	Non-Q-Wave Infarction and Ostial Left Coronary Obstruction Due to Giant Lamblé's Excrescences of the Aortic Valve. <i>Circulation</i> , 1999, 99, 1919-1921.	1.6	15
140	Percutaneous Transcatheter Management of Giant Coronary Aneurysms. <i>Circulation</i> , 1999, 100, E8-E11.	1.6	15
141	Late Stent Thrombosis: The Last Remaining Obstacle in Coronary Interventional Therapy. <i>Current Cardiology Reports</i> , 2012, 14, 408-417.	1.3	15
142	Evolution of intravascular assessment of coronary anatomy and physiology: from ultrasound imaging to optical and flow assessment. <i>European Journal of Clinical Investigation</i> , 2013, 43, 996-1008.	1.7	15
143	Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. <i>International Journal of Cardiology</i> , 2017, 246, 20-25.	0.8	15
144	Guidelines for Patient-Reported Outcomes in Clinical Trial Protocols. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 450.	3.8	15

#	ARTICLE	IF	CITATIONS
145	Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation. JACC: Cardiovascular Interventions, 2018, 11, 1277-1286.	1.1	14
146	Hemoglobin A1c and Cardiovascular Outcomes Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2021, 14, 388-397.	1.1	14
147	Cusp Overlap Technique: Should It Become the Standard Implantation Technique for Self-expanding Valves?. Current Cardiology Reports, 2021, 23, 154.	1.3	14
148	Factors Affecting Bleeding and Stent Thrombosis in Clinical Trials Comparing Bivalirudin With Heparin During Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2015, 8, e002789.	1.4	13
149	Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2016, 9, e003272.	1.4	13
150	Ischemia-reperfusion injury and ischemic postconditioning in acute myocardial infarction: Lost in translation. Catheterization and Cardiovascular Interventions, 2017, 90, 1068-1069.	0.7	13
151	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheterization and Cardiovascular Interventions, 2017, 89, E217-E225.	0.7	13
152	Calculated Serum Osmolality, Acute Kidney Injury, and Relationship to Mortality after Percutaneous Coronary Intervention. CardioRenal Medicine, 2019, 9, 160-167.	0.7	13
153	Excimer laser coronary atherectomy for uncrossable coronary lesions. A multicenter registry. Catheterization and Cardiovascular Interventions, 2020, 98, 1241-1249.	0.7	13
154	Patient-specific computational simulation of coronary artery bifurcation stenting. Scientific Reports, 2021, 11, 16486.	1.6	13
155	Surgical Revascularization versus Percutaneous Coronary Intervention and Optimal Medical Therapy in Diabetic Patients with Multi-Vessel Coronary Artery Disease. Progress in Cardiovascular Diseases, 2015, 58, 306-315.	1.6	12
156	Efficacy and safety of routine thrombus aspiration in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An updated systematic review and meta-analysis of randomized controlled trials. Catheterization and Cardiovascular Interventions, 2016, 87, 650-660.	0.7	12
157	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. Circulation: Cardiovascular Interventions, 2016, 9, e002995.	1.4	12
158	Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention. American Journal of Cardiology, 2017, 119, 1166-1172.	0.7	12
159	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age. JACC: Cardiovascular Interventions, 2019, 12, 983-992.	1.1	12
160	Use of a pneumatic compression system (FEMOSTOPB®) as a treatment option for femoral artery pseudoaneurysms after percutaneous cardiac procedures. Catheterization and Cardiovascular Diagnosis, 1996, 39, 138-142.	0.7	11
161	Art and Science of Cerebrovascular Event Prevention After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	11
162	Bivalirudin Is Associated With Improved In-Hospital Outcomes Compared With Heparin in Percutaneous Vascular Interventions. Circulation: Cardiovascular Interventions, 2016, 9, e002823.	1.4	11

#	ARTICLE	IF	CITATIONS
163	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. <i>International Journal of Cardiology</i> , 2017, 243, 132-139.	0.8	11
164	Impact of insulin treated and non-insulin treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 298-308.	0.7	11
165	A sex paradox in clinical outcomes following complex percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2021, 329, 67-73.	0.8	11
166	Outcomes in Valve-in-Valve Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2022, 172, 81-89.	0.7	11
167	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Tj ETQq1 1 0.784314 rgBT /Over 2017, 120, 904-910.	0.7	10
168	Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial. <i>International Journal of Cardiology</i> , 2019, 297, 22-29.	0.8	10
169	Composite Outcomes in Coronary Bypass Surgery Versus Percutaneous Intervention. <i>Annals of Thoracic Surgery</i> , 2014, 97, 1983-1990.	0.7	9
170	Performance of currently available risk models in a cohort of mechanically supported high-risk percutaneous coronary intervention – From the PROTECT II randomized trial. <i>International Journal of Cardiology</i> , 2015, 189, 272-278.	0.8	9
171	One-year results of the ICON (ionic versus non-ionic contrast to obviate worsening) Tj ETQq1 1 0.784314 rgBT /Over Cardiovascular Interventions, 2016, 87, 703-709.	0.7	9
172	Bleeding After Aortic Valve Replacement Matters. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1447-1448.	1.1	9
173	Outcomes by Gender and Ethnicity After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2019, 123, 1941-1948.	0.7	9
174	Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095491.	0.7	9
175	Anatomic classification of mitral annular calcification for surgical and transcatheter mitral valve replacement. <i>Journal of Cardiac Surgery</i> , 2021, 36, 2410-2418.	0.3	9
176	Aspirin, Platelet P2Y12 Receptor Inhibitors, and Other Oral Antiplatelets. <i>Interventional Cardiology Clinics</i> , 2013, 2, 527-535.	0.2	8
177	Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 391-400.	0.7	8
178	Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 1027-1037.	0.7	8
179	Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12457.	1.1	8
180	Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. <i>International Journal of Cardiology</i> , 2019, 287, 59-61.	0.8	8

#	ARTICLE	IF	CITATIONS
181	Trends and Outcomes of Intravascular Imaging-guided Percutaneous Coronary Intervention in the United States. <i>Critical Pathways in Cardiology</i> , 2020, 19, 69-74.	0.2	8
182	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E704-E715.	0.7	8
183	Selection of the Optimal Candidate to MitraClip for Secondary Mitral Regurgitation: Beyond Mitral Valve Morphology. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 585415.	1.1	8
184	Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 20-29.	1.0	8
185	Randomized Clinical Trial on Prevention of Radial Occlusion After Transradial Access Using Nitroglycerin. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1009-1018.	1.1	8
186	Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2019, 123, 1788-1795.	0.7	7
187	Temporal trends of survival and utilization of mechanical circulatory support devices in patients with in-hospital cardiac arrest secondary to ventricular tachycardia/ventricular fibrillation. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 578-587.	0.7	7
188	Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004945.	0.9	7
189	Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention. <i>American Heart Journal</i> , 2019, 207, 10-18.	1.2	7
190	Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 383, e66.	13.9	7
191	Cardiovascular outcomes after percutaneous coronary intervention on bifurcation lesions with moderate to severe coronary calcium: A single-center registry study. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 35-42.	0.7	7
192	Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 649-657.	1.5	7
193	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E908-E917.	0.7	7
194	Balloon-Expandable versus Self-Expandable Valves in Transcatheter Aortic Valve Implantation: Complications and Outcomes from a Large International Patient Cohort. <i>Journal of Clinical Medicine</i> , 2021, 10, 4005.	1.0	7
195	Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. <i>American Journal of Cardiology</i> , 2016, 118, 1661-1668.	0.7	6
196	Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI. <i>JAMA Cardiology</i> , 2017, 2, 673.	3.0	6
197	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. <i>International Journal of Cardiology</i> , 2018, 263, 24-28.	0.8	6
198	Net clinical benefit of patent foramen ovale closure in patients with cryptogenic stroke: Meta-analysis and meta-regression of randomized trials. <i>International Journal of Cardiology</i> , 2018, 266, 75-80.	0.8	6

#	ARTICLE	IF	CITATIONS
199	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007734.	1.4	6
200	Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: Results from a large single-center registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 558-564.	0.7	6
201	Prognostic Impact of High-Sensitivity C-Reactive Protein in Patients Undergoing Percutaneous Coronary Intervention According to BMI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2882-2892.	1.1	6
202	Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI : TWILIGHT-SYNERGY. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 63-71.	0.7	6
203	Sex-Related Differences in the Prevalence and Prognostic Value of the Academic Research Consortium for High Bleeding Risk Criteria. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010392.	1.4	6
204	Myocardial infarction after cardiac surgery: When to intervene?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 165, 1195-1201.	0.4	6
205	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 282-293.	1.1	6
206	Comparison of Transaortic and Subclavian Approaches for Transcatheter Aortic Valve Replacement in Patients with No Transfemoral Access Options. <i>Structural Heart</i> , 2018, 2, 463-468.	0.2	5
207	Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 42-51.	1.0	5
208	Adjunct Pharmacotherapy After Transcatheter Aortic Valve Replacement. <i>Interventional Cardiology Clinics</i> , 2019, 8, 357-371.	0.2	5
209	Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E377-E386.	0.7	5
210	Noncontrast Nephropathy After Percutaneous Mitral Valve Edge-to-Edge Repair. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2474-2476.	1.2	5
211	Endothelial Progenitor Cells in Coronary Atherosclerosis and Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2022, 42, 94-99.	0.3	5
212	Timing of mechanical circulatory support during primary angioplasty in acute myocardial infarction and cardiogenic shock: Systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2022, , .	0.7	5
213	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 707-716.	1.4	5
214	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. <i>EuroIntervention</i> , 2022, 17, 1330-1339.	1.4	5
215	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. <i>EuroIntervention</i> , 2023, 19, e807-e831.	1.4	5
216	Open Versus Endovascular Stent Graft Repair of Abdominal Aortic Aneurysms. <i>Angiology</i> , 2014, 65, 677-682.	0.8	4

#	ARTICLE	IF	CITATIONS
217	Second-Generation Drug-Eluting Stents and Bioresorbable Vascular Scaffolds in Patients With Diabetes. JACC: Cardiovascular Interventions, 2014, 7, 494-496.	1.1	4
218	Antithrombotic strategy variability in Atrial fibrillation and obstructive coronary disease revascularized with PCI: rationale and study design of the prospective observational multicenter AVIATOR 2 registry. American Heart Journal, 2015, 170, 1234-1242.	1.2	4
219	Cerebrovascular Events After a Primary Percutaneous Coronary Intervention Strategy for Acute ST-Segment Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	4
220	Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheterization and Cardiovascular Interventions, 2017, 90, 1016-1026.	0.7	4
221	Transfemoral PCI skill: Use it or lose it. But #RadialFirst. Catheterization and Cardiovascular Interventions, 2018, 92, 842-843.	0.7	4
222	Transpulmonary electrotherapy for reduction of lung viral load of SARS-CoV-2 in patients with COVID-19. Medical Hypotheses, 2020, 143, 110071.	0.8	4
223	Bioprosthetic Valve Thrombosis: Insights from Transcatheter and Surgical Implants. Structural Heart, 2020, 4, 382-388.	0.2	4
224	Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration. Catheterization and Cardiovascular Interventions, 2021, 97, 797-804.	0.7	4
225	Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI. Journal of Thrombosis and Thrombolysis, 2022, 53, 380-389.	1.0	4
226	Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris. American Journal of Cardiology, 2022, 168, 47-54.	0.7	4
227	Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry). American Journal of Cardiology, 2022, 172, 73-80.	0.7	4
228	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS120009495.	1.4	4
229	A Biomarker-Enhanced Model for Prediction of Acute Kidney Injury and Cardiovascular Risk Following Angiographic Procedures: CASABLANCA AKI Prediction Substudy. Journal of the American Heart Association, 2022, 11, e025729.	1.6	4
230	Myocardial Damage After TAVR Assessed With CMR. Journal of the American College of Cardiology, 2014, 64, 358-360.	1.2	3
231	Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study. Journal of Thrombosis and Thrombolysis, 2016, 42, 186-196.	1.0	3
232	1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration. Cardiovascular Revascularization Medicine, 2020, 21, 1542-1547.	0.3	3
233	Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry. International Journal of Cardiology, 2021, 322, 65-69.	0.8	3
234	Prevalence and prognostic impact of hsCRP elevation are age-dependent in women but not in men undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2021, 97, E936-E944.	0.7	3

#	ARTICLE	IF	CITATIONS
235	Subacute Aortic Root and Valve Thrombosis following Transcatheter Aortic Valve Replacement in a Left Ventricular Assist Device Patient: From One Problem to the Next. Case, 2021, 5, 97-100.	0.1	3
236	Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions (SCAI) 2021 think tank. Catheterization and Cardiovascular Interventions, 2021, 98, 904-913.	0.7	3
237	Prevalence and Impact of High Bleeding Risk in Patients Undergoing Left Main Artery Disease PCI. JACC: Cardiovascular Interventions, 2021, 14, 2447-2457.	1.1	3
238	Outcomes and feasibility of redo TAVR after Sapien 3 Ultra TAVR in extremely undersized versus nominally sized annuli. Catheterization and Cardiovascular Interventions, 2022, 99, 1935-1944.	0.7	3
239	What to Do When a Patient With Coronary Stents Needs Surgery? —. Journal of the American College of Cardiology, 2014, 64, 2740-2742.	1.2	2
240	Coronary chronic total occlusions: How to dilate the tough ones. Catheterization and Cardiovascular Interventions, 2018, 91, 667-668.	0.7	2
241	Subtotal Occlusion of Left Anterior Coronary Artery in a Professional Athlete. Cardiology, 2018, 140, 71-73.	0.6	2
242	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thrombosis and Haemostasis, 2019, 119, 1704-1711.	1.8	2
243	Management of acute myocardial injury in patients with confirmed or suspected COVID-19. Atherosclerosis, 2020, 305, 58-60.	0.4	2
244	Impact of sex on long-term cardiovascular outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes. Catheterization and Cardiovascular Interventions, 2021, 98, E494-E500.	0.7	2
245	Impact of anemia on short-term outcomes after TAVR : A subgroup analysis from the BRAVO 3 randomized trial. Catheterization and Cardiovascular Interventions, 2021, 98, E870-E880.	0.7	2
246	Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft. Catheterization and Cardiovascular Interventions, 2021, 98, E785-E795.	0.7	2
247	Diabetes mellitus and multivessel coronary artery disease: an ongoing battle for an ideal treatment strategy. Annals of Translational Medicine, 2017, 5, 261-261.	0.7	2
248	Bivalirudin or Heparin Treatment During Transcatheter Valve Interventions: Where are we Now?. Current Pharmaceutical Design, 2016, 22, 1911-1917.	0.9	2
249	Prognostic Value of Baseline Inflammation in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention. Canadian Journal of Cardiology, 2022, 38, 792-800.	0.8	2
250	Perioperative Management of P2Y12 Inhibitors in Patients Undergoing Cardiac Surgery within 1 Year of PCI. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	1.4	2
251	In-stent restenosis of bifurcation lesions: Experience with drug-eluting balloons. Catheterization and Cardiovascular Interventions, 2012, 79, 397-398.	0.7	1
252	Prasugrel in NSTEMI. Journal of the American College of Cardiology, 2014, 64, 2572-2574.	1.2	1

#	ARTICLE	IF	CITATIONS
253	MaXIMAL Benefits in the Elderly?. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1376-1377.	1.2	1
254	Long-Term Clinical Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions. <i>Current Cardiology Reports</i> , 2014, 16, 450.	1.3	1
255	Real Dilemmas Regarding Blood Transfusion. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 447-449.	1.1	1
256	Can Coronary Stent Implantation Complexity Become an Intuitive and Useful Factor to Tailor DAPT Duration?. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1447-1449.	1.1	1
257	Dual Antiplatelet Therapy Duration: A Review of Current Available Evidence. <i>Clinical Therapeutics</i> , 2016, 38, 961-973.	1.1	1
258	Bioresorbable Vascular Scaffolds in Women. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1891-1893.	1.1	1
259	Classification and patterns of bifurcation in-stent restenosis (BISR) in the second generation drug eluting stent era. <i>Hellenic Journal of Cardiology</i> , 2017, 58, 167-168.	0.4	1
260	The quest for a "diabetic" stent. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 892-893.	0.7	1
261	Cardiac enzyme elevation after coronary revascularization. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 224-225.	0.7	1
262	Assessment of transaortic pressure gradient using a coronary pressure wire in patients with mechanical aortic and mitral valve prostheses. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 193-199.	0.7	1
263	The quest for the optimal treatment for in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 300-301.	0.7	1
264	Why females get better longer-term outcomes with TAVR. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 753-754.	0.7	1
265	Leave nothing behind: Promising results for coronary drug-coated balloons in clinical practice. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 189-190.	0.7	1
266	Stent Technology Reaches Maturity?. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2879-2881.	1.1	1
267	Combined and independent impact of coronary artery calcification and inflammation on risk for adverse cardiovascular events after percutaneous coronary intervention: Results from a large single-center registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E278-E286.	0.7	1
268	The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E688-E694.	0.7	1
269	<scp>TAVR</scp> for aortic regurgitation: Not as straightforward!. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 486-487.	0.7	1
270	Single antiplatelet therapy after transcatheter aortic valve implantation: clarity on existing data. <i>European Heart Journal</i> , 2021, 42, 3203-3204.	1.0	1

#	ARTICLE	IF	CITATIONS
271	Hypoattenuated Leaflet Thickening After Transcatheter Aortic Valve Replacement: Additional Data, Yet Still Many Unanswered Questions. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS122011828.	1.4	1
272	Periprocedural myocardial infarction: multiple definitions and still a quest for consensus. <i>European Heart Journal</i> , 2021, , .	1.0	1
273	To excel or to confirm? That is the question. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 944-944.	0.7	0
274	Combination Antithrombotic Management of STEMI with Pharmacoinvasive Strategy, Primary PCI, or Rescue PCI. <i>Interventional Cardiology Clinics</i> , 2013, 2, 573-583.	0.2	0
275	Interventional Pharmacology. <i>Interventional Cardiology Clinics</i> , 2013, 2, xiii-xiv.	0.2	0
276	Long-Term Favorable Coronary Healing After Bioresorbable Scaffold Implantation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2357-2359.	1.2	0
277	Principles of Interventions in Acute Structural Heart Disease. , 2014, , 198-200.		0
278	Statistical Essentials in the Design and Analysis of Clinical Trials. , 2016, , 296-300.		0
279	Right Heart Catheterization and Pulmonary Hemodynamics. , 2016, , 485-490.		0
280	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1307.	1.2	0
281	Integrating invasive hemodynamic parameters into risk stratification of acute myocardial infarction and cardiogenic shock. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 396-397.	0.7	0
282	Transcatheter valve-in-valve for failing bioprosthetic aortic valve: Usually a good idea. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 1412-1413.	0.7	0
283	Left Main PCI With DES Versus CABG. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2823-2825.	1.2	0
284	Overlapping bio-absorbable scaffolds: Aim for D2D technique?. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 1210-1211.	0.7	0
285	Redefining landmarks to improve #safefemoral outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 376-377.	0.7	0
286	Transcatheter valves are a viable option for degenerative surgical mitral bioprostheses. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1095-1096.	0.7	0
287	Positioning of self-expanding transcatheter valve prostheses. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 530-531.	0.7	0
288	Interventional Cardiology Education Through Structured Case Reviews. <i>JACC: Case Reports</i> , 2019, 1, 884-885.	0.3	0

#	ARTICLE	IF	CITATIONS
289	Nothing aches like a heart. Hellenic Journal of Cardiology, 2019, 60, 247-248.	0.4	0
290	Impact of High-Density Lipoprotein Levels on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2020, 137, 1-6.	0.7	0
291	Rolling the rock uphill during left main stenting: The Sisyphus myth in percutaneous coronary intervention?. Catheterization and Cardiovascular Interventions, 2020, 96, 762-763.	0.7	0
292	One-year clinical outcomes in patients with chronic kidney disease treated with COMBO stents: From the COMBO collaboration. Catheterization and Cardiovascular Interventions, 2020, , .	0.7	0
293	Combination antiplatelet/antithrombotic regimens after stenting: Are we forcing too much in this decision?. Catheterization and Cardiovascular Interventions, 2021, 97, 589-590.	0.7	0
294	Chronic coronary total occlusions: Let's make the long story short. Catheterization and Cardiovascular Interventions, 2021, 97, 1184-1185.	0.7	0
295	Shock indices in acute myocardial infarction. Catheterization and Cardiovascular Interventions, 2021, 98, 95-96.	0.7	0
296	Assessing the risk of acute kidney injury after primary PCI: The simpler the sooner the better. Catheterization and Cardiovascular Interventions, 2021, 98, 206-207.	0.7	0
297	Coronary access after valve-in-valve transcatheter aortic valve replacement: Time for a prospective study?. Catheterization and Cardiovascular Interventions, 2021, 98, 605-606.	0.7	0
298	Sodium Bicarbonate, Contrast-Associated Acute Kidney Injury, and Long-Term Outcomes: The End of an Era?. Cardiovascular Revascularization Medicine, 2021, 31, 69-70.	0.3	0
299	Coronary Dissection and Right Heart Failure Salvaged by PCI With Percutaneous Intraluminal Microaxial RV-Assist Support. JACC: Case Reports, 2021, 3, 1612-1616.	0.3	0
300	Statistical Essentials in the Design and Analysis of Clinical Trials. , 0, , 491-501.		0
301	Abstract 18908: Transcatheter Aortic Valve Replacement - 30 Day and 1 Year Outcomes Using Conscious Sedation in Patients Stratified by STS Risk Score. Circulation, 2014, 130, .	1.6	0
302	Abstract 18678: Transcatheter Aortic Valve Replacement -Is Anticoagulation Protective?. Circulation, 2014, 130, .	1.6	0
303	Dual versus single antiplatelet therapy after TAVR: Let's not mix apples and oranges. Cardiovascular Revascularization Medicine, 2021, 34, 54-54.	0.3	0
304	Risk prediction in cardiogenic shock. Catheterization and Cardiovascular Interventions, 2021, 98, 1285-1286.	0.7	0
305	Impact of Race/Ethnicity on Long Term Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents. American Journal of Cardiology, 2022, , .	0.7	0
306	Endovascular treatment of infrarenal aortic stenosis: importance of multimodality imaging. Journal of Invasive Cardiology, 2011, 23, E192-6.	0.4	0

#	ARTICLE	IF	CITATIONS
307	TAVR Through Heavily Calcified Aorta Following Atheroma Retrieval With the "Elevator" Technique. Journal of Invasive Cardiology, 2015, 27, E216-9.	0.4	0
308	Is cardiac surgery backup required for left main stenting?. Catheterization and Cardiovascular Interventions, 2022, 99, 607-608.	0.7	0
309	291 Ticagrelor monotherapy after percutaneous coronary intervention in high-risk patients with prior myocardial infarction: a prespecified twilight substudy. European Heart Journal Supplements, 2021, 23, .	0.0	0
310	Double kissing crush stenting: No pain, no gain?. Catheterization and Cardiovascular Interventions, 2022, 99, 1045-1046.	0.7	0
311	Tailoring the therapy to the patient with mitral and tricuspid regurgitation to avoid adverse long-term outcomes. Catheterization and Cardiovascular Interventions, 2022, 99, 1857-1858.	0.7	0
312	Two years into the COVID-19 pandemic: implications for the cardiac catheterization laboratory and its current practices. Journal of Transcatheter Interventions, 0, , 1-7.	0.1	0
313	Contrast-associated acute kidney injury: Type may not matter. Catheterization and Cardiovascular Interventions, 2022, 100, 94-95.	0.7	0